Her research in Cancer Systems Biology focuses on reprogramming cellular metabolic pathways mediated through the unfolded protein response (UPR) in cancer cells that are resistant to antiestrogen therapies. Results show that a change in the genetic makeup of resistant breast cancer cells allows increased production of a protein (MYC) that can directly influence the biochemical pathways and promote cell survival. The goal is to construct a model that connects the altered state of cellular metabolism with survival pathways in drug resistant cancer. Knowledge of the reprogramed pathways will help researchers use new or existing therapeutic agents to successfully treat drug-resistant breast cancer.